Go to the main content

Department of Medicine
Clinical Collaboration Unit Translational Immunology

500
501
502
503
560

Address: Otfried-Müller-Str. 10
72076 Tübingen


Administration Office

frontend.sr-only_#{element.icon}: +49 7071 29-83275


frontend.sr-only_#{element.icon}: +49 7071 29-4391


frontend.sr-only_#{element.icon}: Sabrina.augstein@med.uni-tuebingen.de


About us

The Clinical Cooperation Unit Translational Immunology is a multidisciplinary unit that develops and applies novel immunotherapeutics for cancer patients. It draws on experience obtained in decades of research regarding the development of optimized antitumor antibodies and vaccination strategies, combined with our expertise in the treatment of malignant diseases and the clinical evaluation of new therapeutic concepts. We work closely together with the specialists at the other Departments at University Hospital Tübingen that treat cancer patients as well as the Department of Immunology.

From the Laboratory to the Bedside: The Clinical Cooperation Unit Translational Immunology

From the Laboratory to the Bedside: The Clinical Cooperation Unit Translational Immunology

" We have all been waiting for this headline for decades. Unfortunately, we also know that it is not that simple. Developing new therapies in research laboratories and then applying them in the clinic usually takes several years, if not decades. The vision of the Clinical Cooperation Unit Translational Immunology at the University Hospital Tübingen is to close exactly this gap and to bring innovative therapeutic approaches into the clinic as quickly as possible .

Direction

Prof. Dr. med. Helmut Salih

Medical director

Office:

Phone number: +49 7071 29-83275

Fax number: +49 7071 29-4391

E-mail address: Sabrina.augstein@med.uni-tuebingen.de

Person profile: More about the person

Portraitfoto

PD Dr. med. Juliane Walz

Medical director

Person profile: More about the person

Clinical studies

P-pVAC-SARS-COV-2.

First-in-man study to investigate the safety, tolerability, and immunogenicity of a peptide-based COVID-19 vaccine. (completed)

Results of the study

B-pVAC-SARS-COV-2

Phase II study in participants with congenital or acquired B-cell defect or antibody deficiency. (Currently seeking participants. Please contact us via the adjacent e-mail address)

Information about the study


COR-101
First-in-human study to evaluate the safety, tolerability and efficacy of the Fc-modified antibody COR-101 in patients with moderate to severe COVID-19 disease.

Synopsis

Information about the study

FLYSYN-101

First in man study to evaluate the safety, tolerability and preliminary efficacy of the Fc-optimized FLT3 antibody FLYSYN for the treatment of acute myeloid leukemia patients with minimal residual disease.

Synopsis

Proprietary Phase II study in patients with refractory or relapsed chronic lymphocytic leukemia (belimumab in combination with rituximab/venetoclax).

Information about the study

Synopsis

iVAC-CLL01

Patient-individualized peptide vaccination after first line therapy of CLL

iVAC-XS15-CLL01

Personalized peptide vaccination in combination with the TLR2 ligand XS15 for CLL patients under ibrutinib treatment. 

Synopsis

DKTK_PMO_1605

First in human study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration resistant prostate carcinoma

Start of recruitment planned Q4/2019

Synopsis

ProSperA_CC-1

Application study to investigate the safety, tolerability and efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients biochemical recurrence of prostate cancer.

Synopsis PDF

Information about the study

PSMAxCD3_SCC_01

First-in-man study to evaluate the safety, tolerability and efficacy of the bispecific PSMAxCD3 antibody CC-1 alone or in combination with checkpoint inhibition in patients with squamous cell carcinoma of the lung.

Synopsis

Study Info


Patient individual immunotherapy concepts

The direct link between research and patient care enables us to offer our patients newly developed and personalized immunotherapic concepts for tumor diseases.

Appointments

Please note that for enquiries regarding participation in our clinical trials or for medical consulation on cancer immunotherapy concepts, it is mandatory that the treating physician beforehand provides your treatment documents (current doctor's letter, imaging findings, etc.), ideally via e-mail:

E-mail address: KKETI@med.uni-tuebingen.de


Office for clinical studies:

Sabrina Sauter
Hannah Zug
Janine Nebel

+49 7071 29-82834


Neuigkeiten

Pressemeldung
17.11.22

Immuntherapiestudie für Patienten mit biochemischem Rezidiv des Prostatakarzinoms

Prostatakrebs gehört zu den häufigsten Krebserkrankungen von Männern in Deutschland. Wenn der Tumor voranschreitet und Tochtergeschwüre in anderen Organen bildet (sogenannte Metastasen), ist das Prostatakarzinom bisher nicht heilb…

Mehr erfahren
Pressemeldung
03.02.22

Forschungsteam startet Phase I-Studie bei Patientinnen und Patienten mit metastas

Das Studienteam der Klinischen Kooperationseinheit (KKE) Translationale Immunologie an der Medizinischen Universitätsklinik Tübingen startet eine klinische Phase I-Studie, die Sicherheit, Verträglichkeit und Wirksamkeit des bispez…

Mehr erfahren
Pressemeldung
20.01.22

Therapiestudie für Patientinnen und Patienten mit chronisch lymphatischer Leukämi

An der Klinischen Kooperationseinheit (KKE) Translationale Immunologie (Ärztlicher Direktor Prof. Helmut Salih) der Medizinischen Universitätsklinik in Tübingen sowie an zehn Partnerstandorten in Deutschland startet eine Therapies…

Mehr erfahren
Pressemeldung
23.11.21

Eigenentwickelter Impfstoff gegen SARS-CoV-2 zeigt starke Immunantwort

Am Universitätsklinikum Tübingen wurde im November 2020 unter Leitung von Prof. Dr. Juliane Walz in der KKE Translationale Immunologie der Medizinischen Klinik (Ärztlicher Direktor Prof. Dr. Helmut Salih) die klinische Erprobung e…

Mehr erfahren
Pressemeldung
12.11.21

Bispezifischer Antikörper gegen Prostatakrebs zeigt erste positive Ergebnisse

Das Prostatakarzinom gilt als die zweithäufigste Krebserkrankung bei Männern. Metastasiert der Tumor, ist das Prostatakarzinom bislang auch nicht heilbar. Um die Erkrankung jedoch effektiv zu behandeln und bei Betroffenen eine deu…

Mehr erfahren
Pressemeldung
28.10.21

Eigenentwickelter Impfstoff gegen SARS-CoV-2 speziell für Krebserkrankte und Immu

Im Juni dieses Jahres startete am Universitätsklinikum Tübingen unter Leitung von Prof. Dr. Juliane Walz in der KKE Translationale Immunologie der Medizinischen Klinik (Ärztl. Direktor Prof. Helmut Salih) die klinische Erprobung e…

Mehr erfahren
Pressemeldung
28.09.21

Immuntherapie gegen Blutkrebs schreitet erfolgreich voran

Die Chronisch Lymphatische Leukämie (CLL) ist die häufigste Leukämieerkrankung bei Erwachsenen. Sie verläuft zwar zumindest in den meisten Fällen langsam, ist jedoch bisher nicht heilbar. Seit Dezember 2020 testet eine klinische P…

Mehr erfahren
Pressemeldung
21.06.21

Neuartiger Impfstoff gegen SARS-CoV-2 speziell für Patienten mit Krebserkrankunge

Am Universitätsklinikum Tübingen startet in diesen Tagen die klinische Erprobung eines eigenentwickelten Impfstoffs gegen SARS-CoV-2, der speziell für Patientengruppen mit Antikörpermangel konzipiert ist. Der Impfstoff zielt hochs…

Mehr erfahren
Pressemeldung
21.04.21

Klinischer Studienstart mit neuem Antikörper gegen Sars-CoV-2 in Tübingen

Wirksame Medikamente gegen COVID-19 sind in der aktuellen Coronavirus-Pandemie nach wie vor rar. Auch wenn sich der Blick seit Wochen vorrangig auf die Ermöglichung einer raschen Impfung richtet, wird es künftig viele Menschen geb…

Mehr erfahren
Pressemeldung
11.01.21

Neuer therapeutischer Impfstoff gegen chronische Leukämie wird erprobt

Die Chronisch Lymphatische Leukämie (CLL) ist die häufigste Leukämieerkrankung bei Erwachsenen, die zwar meist langsam verläuft, jedoch bisher nicht heilbar ist. In der Klinischen Kooperationseinheit (KKE) Translationale Immunolog…

Mehr erfahren
Pressemeldung
17.07.19

Krebsstammzellen für das Immunsystem sichtbar machen

Leukämie-Stammzellen schützen sich vor der Immunabwehr, indem sie ein Zielmolekül der Killerzellen von ihrer Oberfläche verschwinden lassen. Doch dieser Schutzmechanismus lässt sich mit Medikamenten überwinden. Welche neuen Therap…

Mehr erfahren

Research

The increasing understanding of the mechanisms underlying host-tumor interaction led to development of strategies that harness antitumor immunity for cancer treatment. However, while immunotherapy meanwhile has become a mainstay of tumor therapy, there is still ample room for improvement. Some patients do not respond to presently available approaches at all, others for limited time only, and for many cancer entities so far no immunotherapeutic strategies are available. In our view, this calls for efforts to more rapidly translate promising results from research to clinical application. To achieve this superordinate goal, our work focusses on the following key aspects:

Here we investigate the role of various immunoregulatory molecules involved in host-tumor interaction, in particular with putative tumor stem cells. Beyond improving the understanding of tumor biology per se, these studies aim to identify new target molecules for immunotherapeutic approaches and to identify prognostic markers for disease progression and response in patients. We further investigate how "conventional" systemic tumor therapeutics influence the immune response to enable rational combinations with immunotherapy. In addition, the development of valid model systems for testing novel strategies prior to application in humans is an important basis to develop rational immunotherapeutics.

The "preclinical" work mentioned above provides the basis for the second focus of our work, which is clearly focused on clinical application. This includes the development of optimized mono- and bispecific antibodies, novel immunocytokines and personalized peptide vaccination strategies. Our efforts cover the entire process, from conception and manufacture to clinical application in patients. This enables the rapid translation of results from basic research to novel therapies for cancer patients ("bench to bedside"). The feasibility of our approach is reflected by our various clinical studies with in-house developed  immunotherapeutics.

Clinical studies

Social Media

Education and Career

Education

The rapid developments in tumor immunology and immunotherapy during the recent years call for a greater focus on this topic during academic education. Therefore, the CCU Translational Immunology participates in numerous classes and curricula in human medicine, biochemistry, biology and molecular medicine. In addition to strengthening basic immunological education, in our view it is particularly important to inspire students of human medicine for research for tumor immunology. Likewise it is equally important to illustrate the potential, but also the difficulties of translation in the field of immunotherapy to students of non-clinical natural sciences. Accordingly, we consider an early involvement of students and later also resident physicians and PhD students in translational research as a very important aspect of academic education. The various research groups within the CCU Translational Immunology offer the opportunity to gain insights into basic research and translational projects during internships, bachelor's and master's theses as well as medical and scientific doctoral dissertations. We provide numerous opportunities for further education within the framework of the iFIT excellence cluster, the National Center for Tumor Diseases (NCT) Southwest and by attending national and international meetings as well as workshops and courses for career development.

Career

The CCU Translational Immunology offers resident physicians and specialists of the various disciplines involved in treatment of cancer patients the opportunity to gain experience in the development and conduct of clinical trials within the scope of a rotation. With support of our experienced lab staff, this also provides a chance to conduct research projects with the aim to publish scientific work, which enables the application for internal and external research funds as well as research scholarships for stays abroad. For a rotation to the CCU Translational Immunology, a minimum of 2 years clinical experience is mandatory. 

Applications from motivated students for a position to conduct a master's thesis or a medical or scientific doctoral thesis are welcome. The same applies to Ph.D. scientists interested in our field.

Contact

Administrative office
Sabrina Augstein

+49 7071 29-83275

+49 7071 29-4391


E-mail address: Sabrina.augstein@med.uni-tuebingen.de


Certificates and Associations

Go to the main content
Cookie Einstellungen
Bitte treffen Sie eine Auswahl um fortzufahren.
Weitere Informationen zu den Auswirkungen Ihrer Auswahl finden Sie unter Hilfe.
 
Um fortfahren zu können, müssen Sie eine Cookie-Auswahl treffen.

Cookies zulassen:
Wir setzen das Analysetool Google Analytics ein, um Besucher-Informationen wie z.B. Browser, Land, oder die Dauer, wie lange ein Benutzer auf unserer Seite verweilt, zu messen. Ihre IP-Adresse wird anonymisiert übertragen, die Verbindung zu Google ist verschlüsselt.

Nur notwendige Cookies zulassen:
Wir verzichten auf den Einsatz von Analysetools. Es werden jedoch technisch notwendige Cookies, die eine reibungslose Navigation und Nutzung der Webseite ermöglichen, gesetzt (beispielsweise den Zugang zum zugangsbeschränkten Bereich erlauben).

Sie können Ihre Cookie-Einstellung jederzeit auf der Seite Datenschutzerklärung ändern. Zum Impressum.

Zurück

Cookies zulassen Nur notwendige Cookies zulassen